PURPOSE: To determine whether consolidation therapy with high-dose melphalan, etoposide, and total-body irradiation (TBI) with autologous stem-cell support would improve the prognosis for patients with newly diagnosed metastatic Ewing's sarcoma (ES). PATIENTS AND METHODS: Thirty-two eligible patients with newly diagnosed ES metastatic to bone and/or bone marrow were enrolled onto this study. Treatment was initially comprised of five cycles of induction chemotherapy (cyclophosphamide, doxorubicin, and vincristine alternating with ifosfamide and etoposide) and local control. Peripheral-blood stem-cell collection was performed after the second cycle of chemotherapy, with delay if the bone marrow was persistently involved. If patients had a good response to initial therapy, they proceeded to consolidation therapy with melphalan, etoposide, TBI, and stem-cell support. RESULTS: Of the 32 eligible patients, 23 proceeded to high-dose therapy consolidation. Of the nine patients who did not proceed to consolidation, four were secondary to progressive disease and two were secondary to toxicity. Three patients died from toxicity during the high-dose phase of the therapy. The majority of the patients who underwent high-dose consolidation therapy experienced relapse and died with progressive disease. Two-year event-free survival (EFS) for all eligible patients is 20%. The 2-year post-stem-cell reconstitution EFS for the subset of 23 patients who received consolidation therapy is 24%. Analysis of peripheral-blood stem-cell collections by molecular techniques for minimal residual disease showed contamination of at least some samples by tumor cells in all three patients with available data. CONCLUSION: Consolidation with high-dose melphalan, etoposide, TBI, and autologous stem-cell support failed to improve the probability of EFS in this cohort of patients with newly diagnosed metastatic ES.
PURPOSE: To determine whether consolidation therapy with high-dose melphalan, etoposide, and total-body irradiation (TBI) with autologous stem-cell support would improve the prognosis for patients with newly diagnosed metastatic Ewing's sarcoma (ES). PATIENTS AND METHODS: Thirty-two eligible patients with newly diagnosed ES metastatic to bone and/or bone marrow were enrolled onto this study. Treatment was initially comprised of five cycles of induction chemotherapy (cyclophosphamide, doxorubicin, and vincristine alternating with ifosfamide and etoposide) and local control. Peripheral-blood stem-cell collection was performed after the second cycle of chemotherapy, with delay if the bone marrow was persistently involved. If patients had a good response to initial therapy, they proceeded to consolidation therapy with melphalan, etoposide, TBI, and stem-cell support. RESULTS: Of the 32 eligible patients, 23 proceeded to high-dose therapy consolidation. Of the nine patients who did not proceed to consolidation, four were secondary to progressive disease and two were secondary to toxicity. Three patients died from toxicity during the high-dose phase of the therapy. The majority of the patients who underwent high-dose consolidation therapy experienced relapse and died with progressive disease. Two-year event-free survival (EFS) for all eligible patients is 20%. The 2-year post-stem-cell reconstitution EFS for the subset of 23 patients who received consolidation therapy is 24%. Analysis of peripheral-blood stem-cell collections by molecular techniques for minimal residual disease showed contamination of at least some samples by tumor cells in all three patients with available data. CONCLUSION: Consolidation with high-dose melphalan, etoposide, TBI, and autologous stem-cell support failed to improve the probability of EFS in this cohort of patients with newly diagnosed metastatic ES.
Authors: S L Gardner; J Carreras; C Boudreau; B M Camitta; R H Adams; A R Chen; S M Davies; J R Edwards; A C Grovas; G A Hale; H M Lazarus; M Arora; P J Stiff; M Eapen Journal: Bone Marrow Transplant Date: 2008-02-04 Impact factor: 5.483
Authors: Crystal L Mackall; Eunice H Rhee; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; Donna Bernstein; Merertu Tesso; Lauren M Long; David Grindler; Margret Merino; William Kopp; Maria Tsokos; Jay A Berzofsky; Lee J Helman Journal: Clin Cancer Res Date: 2008-08-01 Impact factor: 12.531
Authors: David Schirmer; Thomas G P Grünewald; Richard Klar; Oxana Schmidt; Dirk Wohlleber; Rebeca Alba Rubío; Wolfgang Uckert; Uwe Thiel; Felix Bohne; Dirk H Busch; Angela M Krackhardt; Stefan Burdach; Günther H S Richter Journal: Oncoimmunology Date: 2016-04-25 Impact factor: 8.110
Authors: Judy L Felgenhauer; Michael L Nieder; Mark D Krailo; Mark L Bernstein; David W Henry; David Malkin; Sylvain Baruchel; Paul J Chuba; Scott L Sailer; Ken Brown; Sarangarajan Ranganathan; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2012-10-12 Impact factor: 3.167
Authors: Erin E Karski; Elizabeth McIlvaine; Mark R Segal; Mark Krailo; Holcombe E Grier; Linda Granowetter; Richard B Womer; Paul A Meyers; Judy Felgenhauer; Neyssa Marina; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2015-08-10 Impact factor: 3.167